Lomustine use in combination with etoposide, cytarabine and melphalan in a brief conditioning regimen for auto-HSCT in patients with lymphoma: the optimal dose

Bone Marrow Transplant. 2014 Sep;49(9):1239-40. doi: 10.1038/bmt.2014.121. Epub 2014 Jun 2.

Authors

K B dos Santos¹, L J Costa², A Atalla³, J Pereira⁴, A E Hallack-Neto³

Affiliations

¹ Universidade Federal de Juiz de Fora, Division of Hematology and Bone Marrow Transplantation, Minas Gerais, Brazil.
² Medical University of South Carolina, Division of Hematology/Oncology, Charleston, SC, USA.
³ Universidade Federal de Juiz de Fora, Division of Clinical Medical, Minas Gerais, Brazil.
⁴ Universidade Federal de São Paulo, Division of Hematology, São Paulo, Brazil.

PMID: 24887380
DOI: 10.1038/bmt.2014.121

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Cohort Studies
Cytarabine / administration & dosage
Etoposide / administration & dosage
Female
Hematopoietic Stem Cell Transplantation / methods*
Humans
Lomustine / administration & dosage
Lymphoma / drug therapy
Lymphoma / therapy*
Male
Melphalan / administration & dosage
Middle Aged
Transplantation Conditioning / methods*
Young Adult

Substances

Cytarabine
Etoposide
Lomustine
Melphalan